A detailed history of Rafferty Asset Management, LLC transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 160,873 shares of COGT stock, worth $1.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
160,873
Previous 113,686 41.51%
Holding current value
$1.17 Million
Previous $1.23 Million 2.2%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$7.64 - $12.28 $360,508 - $579,456
47,187 Added 41.51%
160,873 $1.25 Million
Q3 2024

Nov 13, 2024

SELL
$8.24 - $11.48 $579,082 - $806,779
-70,277 Reduced 38.2%
113,686 $1.23 Million
Q2 2024

Aug 13, 2024

SELL
$6.01 - $9.04 $3.13 Million - $4.71 Million
-520,897 Reduced 73.9%
183,963 $1.55 Million
Q1 2024

May 13, 2024

BUY
$4.38 - $9.02 $1.82 Million - $3.75 Million
416,189 Added 144.17%
704,860 $4.74 Million
Q4 2023

Feb 13, 2024

BUY
$4.06 - $10.08 $393,389 - $976,691
96,894 Added 50.52%
288,671 $1.7 Million
Q3 2023

Nov 13, 2023

SELL
$9.69 - $13.34 $139,206 - $191,642
-14,366 Reduced 6.97%
191,777 $1.87 Million
Q2 2023

Aug 11, 2023

SELL
$9.85 - $13.24 $354,856 - $476,984
-36,026 Reduced 14.88%
206,143 $2.44 Million
Q1 2023

May 11, 2023

SELL
$10.04 - $15.5 $820,448 - $1.27 Million
-81,718 Reduced 25.23%
242,169 $2.61 Million
Q4 2022

Feb 13, 2023

BUY
$10.65 - $14.84 $1.22 Million - $1.7 Million
114,511 Added 54.69%
323,887 $3.74 Million
Q3 2022

Nov 14, 2022

BUY
$9.39 - $16.99 $1.97 Million - $3.56 Million
209,376 New
209,376 $3.12 Million

Others Institutions Holding COGT

About Cogent Biosciences, Inc.


  • Ticker COGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,758,300
  • Market Cap $477M
  • Description
  • Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...
More about COGT
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.